Brodalumab Withdrawn Phase 4 Trials for Moderate to Severe Plaque Psoriasis Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT04614298A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis